Promentis Pharmaceuticals
Milwaukee, US · Delaware corporation · 3 known investors
Find your way into Promentis Pharmaceuticals
130 people in our graph share verified history with the Promentis Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Tiffany Yuunlockedknows Thomas Beck · together at F-Prime Capital
×11knows the team · via F-Prime Capital
Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing oral compounds targeting the System xc- glutamate pathway to treat neuropsychiatric disorders. Its lead indication is trichotillomania, and its work extends to other obsessive-compulsive, addictive, and CNS conditions.
Founders & leadership
DB
David Baker, PhDFounder
DL
Daniel LawtonExecutive
TB
CB
Chad BeyerExecutive
CE
Chad E Beyer, PhDExecutive
Board
KV
SS
SS
PS
Patrick Schwarz-SchuetteBoard director
KV
Klaus Veitinger, MD, PhDBoard director
EB
Ed Barthell, MDBoard director
VN
Virinder Nohria, PhDBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$29.7M disclosed across 4 rounds · 2013–2019
▶$2.5MraisedDec 2019 · 8 investors · PharmaceuticalsRule 506(b)
▶$2.5MraisedDec 2019 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Chad BeyerExecutive Officer
- Steve SquintoDirector
- Thomas BeckDirector
- Patrick Schwarz-SchuetteDirector
- Klaus VeitingerDirector
- Daniel LawtonExecutive Officer, Director
- Stacey SeltzerDirector
- Offering amount
- $6M
- Amount sold
- $2.5M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.6MraisedSep 2017 · 8 investors · PharmaceuticalsRule 506(b)
▶$17.6MraisedSep 2017 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Daniel LawtonExecutive Officer, Director
- Chad BeyerExecutive Officer
- Tom BeckExecutive Officer, Director
- Steve SquintoDirector
- Stacey SeltzerDirector
- Patrick Schwarz-SchuetteDirector
- Klaus VeitingerExecutive Officer, Director
- Offering amount
- $17.6M
- Amount sold
- $17.6M
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.8MraisedOct 2016 · 8 investors · PharmaceuticalsRule 506(b)
▶$8.8MraisedOct 2016 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Daniel LawtonExecutive Officer, Director
- Klaus VeitingerExecutive Officer, Director
- Steve SquintoDirector
- Tom BeckExecutive Officer, Director
- Stacey SeltzerDirector
- Patrick Schwarz-SchuetteDirector
- Chad BeyerExecutive Officer
- Offering amount
- $8.8M
- Amount sold
- $8.8M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$820.2KraisedJan 2014 · 6 investors · PharmaceuticalsRule 506(b)
▶$820.2KraisedJan 2014 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Klaus Veitinger, MD, PhDDirector
- David Baker, PhDDirector
- Ed Barthell, MDDirector
- Chad E Beyer, PhDExecutive Officer, Director
- Daniel LawtonDirector
- Patrick Schwarz-SchuetteDirector
- Virinder Nohria, PhDDirector
- Offering amount
- $2.9M
- Amount sold
- $820.2K
- Proceeds to insiders
- $240K
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Catalent19 shared keywordsCatalent is a global Contract Development and Manufacturing Organization (CDMO) that helps pharma, biotech, and self-care companies develop, manufacture, and deliver drug products and consumer health solutions. Its services span oral dose, biologics, specialty, and clinical supply, from early-stage design through commercial manufacturing.
Inven14 shared keywordsInven provides AI-powered workflows for investment and consulting firms to automatically generate company materials such as market maps, financial profiles, and competitive landscapes from structured data. The platform serves management consulting firms and investment professionals who need to produce analyst-ready documents and decks at scale.
Companies competing with Promentis Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $151.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $508.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Promentis Pharmaceuticals do?
- Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing oral compounds targeting the System xc- glutamate pathway to treat neuropsychiatric disorders. Its lead indication is trichotillomania, and its work extends to other obsessive-compulsive, addictive, and CNS conditions.
- Who founded Promentis Pharmaceuticals?
- Promentis Pharmaceuticals was founded by David Baker, PhD.
- Who are Promentis Pharmaceuticals's investors?
- Promentis Pharmaceuticals's investors include Aisling Capital, F-Prime Capital, OrbiMed.
- How much funding has Promentis Pharmaceuticals raised?
- Promentis Pharmaceuticals has disclosed $29.7M raised across 4 rounds.
- Where is Promentis Pharmaceuticals headquartered?
- Promentis Pharmaceuticals is headquartered in Milwaukee, US.